Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Gregory Y. H. Lip
Dr. Healey Jeff
Presenter | see Discussant report
Access to the congress content with ESC Congress 365
List of Authors: Assoc. .Prof. Jeff Healey / CanadaCo-authors: Dr. Jonas Oldgren, Sweden/Dr. Amit Parekh, USA/Dr. Jun Zhu, China/Dr. Prem Pais, India/Dr. Patrick Commerford, South Africa/Prof. Michael Ezekowitz, USA/Prof. Lars Wallentin, Sweden/Prof. Stuart J. Connolly, Canada/Prof. Salim Yusuf, Canada
BackgroundAtrial fibrillation (AF) is an important cause of morbidity and mortality in all regions of the world. However; the predisposing conditions and management of AF differ substantially between regions. This multinational registry is the first to report on 1-year outcomes for a large cohort of primary care patients with AF from all regions of the world, including low-income countries.
MethodsThis prospective registry (164 sites in 47 countries) enrolled patients attending an emergency department (ED) with AF as either a primary or secondary diagnosis. Follow-up was obtained at 1-year (± 4 weeks) after presentation to the ED. Outcomes of patients in North America (Canada and USA) were compared with those from 8 major geographic regions. P-values of <0.005 were considered significant.
ResultsA total 15,340 patients were enrolled of whom 11.5% died within 1 year. Compared to patients in North America (11.4%), the one-year mortality rate was significantly lower in Western Europe (8.2%), but twice as high in Latin America (18.5%) and Africa (21.5%). The rate of death was lower (5.5%) among patients who presented to the ED with AF as their primary diagnosis compared to those who presented for other reasons (16.5%). However; rates were similar for patients with rheumatic heart disease (RHD) compared to those without (10.6% vs. 11.7%)In North America, the one-year stroke risk was 3.2%; however the rate was significantly higher in China (7.1%), South-East Asia (7.8%) and Africa (9.1%). The increased stroke risk in these regions was observed for all levels of CHADS2 score and was observed both in patients with and without RHD (RHD: 3.1% vs. 4.6% vs. 12.8% vs. 8.5%; No-RHD: 3.1% vs. 7.6% vs. 7.6% vs. 9.2% respectively). Regional differences in stroke rates did not appear to be the result of variations in OAC use, as the differences in stroke rates were most pronounced among patients with a CHADS2 score > 1 or RHD who were receiving OAC (3.7% vs. 12.1% vs. 12.5% vs. 14.9% respectively). Among patients without RHD, global stroke risk rose stepwise with increasing CHADS2 score: 0 - 1.7%; 1 – 2.7%, 2 – 3.7%, 3 – 6.9%, > 3 – 8.8%.
ConclusionsMore than 10% of patients who are seen in an ED with AF are dead within one year. The rate is twice as high in Latin America and Africa. Stroke risk is higher in China, South-East Asia and Africa than the rest of the world and this difference appears unrelated to differences in RHD, CHADS2 score and OAC use.
Discussant | see Presenter abstract
Gregory Yh Lip
711005 - 711006
Clinical Trial & Registry Update III: Updates on Atrial Fibrillation and Valves
© 2017 European Society of Cardiology. All rights reserved